ASH Clinical News July 2015_updated | Page 65

Contribute to patient empowerment by
discussing what your patients want out
of their inhibitor treatment. How might
NovoSeven® RT work for them?

Room temperature
stable up to 77°F1

Prefilled syringe
means no extra steps to fill
a syringe with diluent1

Everything they need
to prepare and reconstitute
in 1 small box

Hear from Justin and other patients at
NovoSevenRT.com/hcp/SpeakUp
Adverse Reactions
• The most common and serious adverse reactions in clinical trials
are thrombotic events. Thrombotic adverse reactions following the
administration of NovoSeven® RT in clinical trials occurred in 4% of
patients with acquired hemophilia and 0.2% of bleeding episodes
in patients with congenital hemophilia.
Drug Interactions
• Thrombosis may occur if NovoSeven® RT is administered
concomitantly with Coagulation Factor XIII.
Please see Brief Summary of Prescribing Information
on the following page.
Reference: 1. NovoSeven RT [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2015.

Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.
NovoSeven® is a registered trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2015 Novo Nordisk
All rights reserved. 0515-00026983-1
July 2015